SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Govt monitoring supply of various 'protocol drugs' used in treatment of COVID-19: Mandaviya

20 May 2021 Evaluate

Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya has said that the government is monitoring the supply of various 'protocol drugs' like Remdesivir, Enoxaparin, MethylPrednisolone, Dexamethasone, Tocilizumab and Ivermectin used in the treatment of COVID-19. Besides, supply of other drugs like Favipiravir, Amphotericin and Apixamab is also being monitored. He noted that all drugs used in the management of COVID-19 were now available in India by ramping up production and increasing the imports. The availability of these drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand-side management and affordability.

The minister has stated that the Central Drugs Standard Control Organisation (CDSCO) and the National Pharmaceutical Pricing Authority (NPPA) are coordinating with manufacturers to enhance production and getting data about current stock, current capacities, projected production for May 2021. He noted that the number of plants producing Remdesivir has been increased from 20 to 60, resulting in three times more availability in just 25 days. 

Mandaviya further said the government has also enhanced the availability of Tocilizumab injection in the country by importing 20 times more than what was being done in normal times. Besides, production of Dexamethasone (0.5 mg) tablets and injection have been ramped up. Also, production of other critical medications like Enoxaparin Injection, Methylprednisolone Injection, Ivermectin (12 mg) tablet, Favirpiravir, and Amphoterecin B Injection has been enhanced.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: